Advanced Vaccine Delivery
Tuesday 5 May 2009
Prof.dr D.J.A. Crommelin and dr E.C. Beuvery
Modern vaccines often consist of purified macromolecules (proteins, carbohydrates, DNA). Often these antigens are not very immunogenic. The immunogenicity can be improved by incorporating them into multimeric presentation forms, often in the presence of immune stimulating substances called adjuvants. These delivery devices can be adapted for special tasks. It is possible to attach targeting molecules to the antigen carrier in order to improve binding to antigen presenting cells. The vaccine can be incorporated into biodegradable microspheres in order to achieve sustained antigen release or protection from proteolytic enzymes. The vaccine can be designed in such a way that passage through intact skin is facilitated, preventing the use of needles for immunisation.
For students several research possibilities exist in the exciting field of pure science and ‘real life’ products like vaccines. These include the development of delivery systems for meningococcal (and other) vaccines based on (1) targeted liposomes and (2) controlled antigen release from biodegradable polymers.
In addition, it is expected that within a year possibilities exist with respect to dermal, needle free delivery of antigens.
ELISA, Biosensor analysis (BIAcore), electrophoresis, immunisation studies in mice, confocal microscopy, FACS analysis, electrophoresis, particle size measurements (dynamic light scattering), fluorescence spectroscopy
6 or 9 months
Wim Jiskoot, firstname.lastname@example.org, tel. 030-2536970
Gideon Kersten, email@example.com, tel. 030-2742925
www.nvi-vaccin.nl and www.pharm.uu.nl/ffwuk.htm?/english/